Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 1 February 2020 to 31 August 2021
  • Awards: Pump-priming Awards

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly-recognised disease characterised by progressive accumulation of misfolded protein fibrils. It manifests as an infiltrative cardiomyopathy with increased myocardial wall thickness, conduction disease, heart failure, and poor prognosis.

Novel cardiovascular magnetic resonance (CMR) imaging biomarkers such as parametric mapping are highly promising for quantitatively assessing disease burden in patients with ATTR-CM. This project will explore novel and conventional imaging biomarkers for monitoring disease progression and response to treatment in ATTR-CM patients. Quantitative imaging biomarkers that reliably track treatment effects have multiple clinical applications across the spectrum of cardiovascular disease, including potential to inform guidelines, therapeutic regulations, and future clinical trial design in the rapidly evolving field of novel targeted therapies.

Image title:  Short-axis T1 map of the heart in a patient with amyloid cardiomyopathy demonstrating abnormal T1 signal (areas of red within the normal green myocardium) which may be measured quantitatively.

Image of human heart with areas of amyloid cardiomyopathy highlighted in red against normal myocardium highlighted in green.